Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Lilly catches Relay in PI3Ka race via Scorpion acquisition

A spinout will house precision oncology assets from Scorpion

By Lauren Martz, Executive Director, Biopharma Intelligence
January 13, 2025 8:40 PM UTC

Eli Lilly is taking another shot at PI3Ka inhibition to bolster its breast cancer pipeline through a deal to acquire Scorpion. The deal, worth up to $2.5 billion including an undisclosed upfront payment, is also the latest example of a concurrent acquisition and new company spinout. 

Eli Lilly and Co. (NYSE:LLY) will retain lead asset STX-478 from Scorpion Therapeutics Inc., while the remainder of the pipeline will spin out into a new company with Lilly as a minority shareholder. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Eli Lilly and Co.

Relay Therapeutics Inc.

Scorpion Therapeutics Inc.